Login / Signup
Eryn Callihan
ORCID
Publication Activity (10 Years)
Years Active: 2023-2023
Publications (10 Years): 5
Top Topics
Clinical Trial
Metastatic Renal Cell Carcinoma
Phase Ii
Top Venues
Cancer research communications
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Elizabeth R Kessler
,
Eryn Callihan
,
Junxiao Hu
,
Corbin J Eule
,
Geetika Srivastava
,
Douglas J Kemme
,
Praveena Iruku
,
Vishal Rana
,
James Moore
,
Steven R Schuster
,
Mali Amirault
,
Thomas W Flaig
,
Elaine T Lam
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Cancer research communications
3 (6) (2023)
Elizabeth R Kessler
,
Eryn Callihan
,
Junxiao Hu
,
Corbin J Eule
,
Geetika Srivastava
,
Douglas J Kemme
,
Praveena Iruku
,
Vishal Rana
,
James Moore
,
Steven R Schuster
,
Mali Amirault
,
Thomas W Flaig
,
Elaine T Lam
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Cancer research communications
3 (6) (2023)
Elizabeth R Kessler
,
Eryn Callihan
,
Junxiao Hu
,
Corbin J Eule
,
Geetika Srivastava
,
Douglas J Kemme
,
Praveena Iruku
,
Vishal Rana
,
James Moore
,
Steven R Schuster
,
Mali Amirault
,
Thomas W Flaig
,
Elaine T Lam
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Cancer research communications
3 (6) (2023)
Elizabeth R Kessler
,
Eryn Callihan
,
Junxiao Hu
,
Corbin J Eule
,
Geetika Srivastava
,
Douglas J Kemme
,
Praveena Iruku
,
Vishal Rana
,
James Moore
,
Steven R Schuster
,
Mali Amirault
,
Thomas W Flaig
,
Elaine T Lam
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Cancer research communications
3 (6) (2023)
Elizabeth R Kessler
,
Eryn Callihan
,
Junxiao Hu
,
Corbin J Eule
,
Geetika Srivastava
,
Douglas J Kemme
,
Praveena Iruku
,
Vishal Rana
,
James Moore
,
Steven R Schuster
,
Mali Amirault
,
Thomas W Flaig
,
Elaine T Lam
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Cancer research communications
3 (6) (2023)